# US 2019/0241680 A1 · Bonding tissues and cross-linking proteins with naphthalimide compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241680 A1
- Document ID: US20190241680A1
- Status: Published application
- Kind: A1
- Application number: 15/999,547
- Filed: 2018-08-20
- Published: 2019-08-08
- Earliest claimed: 2003-11-05
- Assignees: Alumend, LLC
- Applicants: Alumend, LLC
- Inventors: Ronald E. Utecht; Kaia L. Kloster; Millard M. Judy; Kevin J. Vaska; James L. Matthews
- Web page: https://patentgrep.com/patent/US20190241680A1

## CPC

- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- A61B 17/00: Surgical instruments, devices or methods (A61B18/00 takes precedence; dental tools A61C3/00; eye surgery A61F9/007; ear surgery A61F11/20)
- A61B 17/08: Wound clamps {or clips, i.e. not or only partly penetrating the tissue (suture bridges A61B17/0466); Devices for bringing together the edges of a wound}
- A61K 8/736: {Chitin; Chitosan; Derivatives thereof}
- A61K 31/722: Chitin, chitosan
- A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}
- A61K 41/0042: {Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61L 24/08: Polysaccharides {(A61L24/043 takes precedence)}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61Q 17/04: Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
- A61Q 19/00: Preparations for care of the skin
- A61K 2800/57: Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
- A61K 2800/81: Preparation or application process involves irradiation
- A61K 2800/94: Involves covalent bonding to the substrate
- A61N 2005/0602: {for treatment of blood vessels}
- A61N 2005/0663: {Coloured light}
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Naphthalimide compounds as used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bone tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabiliation of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

## Claims

### Claim 1

A method for stabilizing an enlarged luminal area of a dilated arterial vessel, comprising:
delivering an effective amount of a compound of formula (II) or a pharmaceutically acceptable salt thereof to an arterial vessel having an arterial lumen at a treatment site thereof;
dilating the arterial vessel at the treatment site via balloon angioplasty, so as to enlarge the arterial lumen; and
delivering an activating agent comprising visible light to the enlarged arterial lumen of the dilated arterial vessel;
wherein the compound of formula (II) is
wherein R and R′ each represents CH2(CH2OCH2)2CH2NH2 and Q represents CH2(CH2OCH2)2CH2, or a pharmaceutically acceptable salt thereof.

### Claim at position 2

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the activating agent is delivered to the dilated arterial vessel intraluminally via a fiber optic guidewire.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dilated arterial vessel has a diameter about 30% greater than the artery in a non-dilated state.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt of the component of formula (II) is delivered to a treatment site of the arterial vessel.

### Claim 10 (depends on 7)

The method of claim 7, wherein the pharmaceutically acceptable salt of the component of formula (II) is delivered to a treatment site of the arterial vessel.

### Claim 11 (depends on 8)

The method of claim 8, wherein the pharmaceutically acceptable salt of the component of formula (II) is delivered to a treatment site of the arterial vessel.
